Retrospective Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2018; 24(20): 2181-2190
Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2181
Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer
Wen-Juan Ma, Xing Wang, Wen-Ting Yan, Zhong-Guo Zhou, Zhi-Zhong Pan, Gong Chen, Rong-Xin Zhang
Wen-Juan Ma, Zhong-Guo Zhou, Zhi-Zhong Pan, Gong Chen, Rong-Xin Zhang, State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China
Wen-Juan Ma, Zhong-Guo Zhou, Zhi-Zhong Pan, Gong Chen, Rong-Xin Zhang, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, Guangdong Province, China
Xing Wang, Wen-Ting Yan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, Hubei Province, China
Zhong-Guo Zhou, Department of Hepatobiliary Surgery, Cancer Center, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China
Zhi-Zhong Pan, Gong Chen, Rong-Xin Zhang, Department of Colorectal Surgery, Cancer Center, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China
Author contributions: All authors helped to perform the research; Ma WJ performed the manuscript writing, experimental procedures and data analysis; Wang X performed the experiments and data analysis; Yan WT contributed to writing of the manuscript and data analysis; Zhou ZG contributed to collecting data and study design; Pan ZZ contributed to data analysis and study design; Chen G contributed to writing of the manuscript and drafting of the study conception; Zhang RX contributed to study design and data analysis.
Supported by the National Natural Science Foundation of China, No. 81502459.
Institutional review board statement: This study was approved by the Sun Yat-sen University Cancer Center Institutional Review Board and Human Ethics Committee.
Informed consent statement: Informed consent was obtained from all individual participants included in the study.
Conflict-of-interest statement: We declare that there is no conflict of interest in this study.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Rong-Xin Zhang, MD, Attending Doctor, Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Dongfeng East Road No. 651, Guangdong 510060, Guangzhou Province, China. zhangrx@sysucc.org.cn
Telephone: +86-20-87343584 Fax: +86-20-87343584
Received: February 28, 2018
Peer-review started: February 28, 2018
First decision: March 15, 2018
Revised: March 21, 2018
Accepted: April 16, 2018
Article in press: April 15, 2018
Published online: May 28, 2018
Processing time: 89 Days and 3.2 Hours
Core Tip

Core tip: It was reported that indoleamine-2,3-dioxygenase 1 (IDO1) is an inhibitory factor that suppresses the T cell response to tumors. In this study, we evaluated IDO1/cyclooxygenase 2 (COX2) expression as an independent prognostic biomarker for colorectal cancer (CRC) patients. In our multivariate Cox model, high coexpression of cytoplasmic IDO1/COX2 was found to be an independent predictor of poor outcome in CRC patients and celecoxib subgroup patients. Our results showed that cytoplasmic IDO1/COX2 coexpression could be used as an independent predictor for poor overall survival in CRC.